Major Setback for Vical - Analyst Blog


Shutterstock photo

Vical Incorporated ( VICL ) recently suffered a major setback with its oncology candidate, Allovectin, failing to meet the primary endpoint in a phase III study.

Top-line results from the phase III trial showed that Allovectin failed to achieve a statistically significant improvement in objective response rate (primary endpoint) and overall survival (secondary endpoint) versus first line chemotherapy.

The study was conducted in metastatic melanoma patients.

Given the disappointing data, Vical has terminated its development program on Allovectin and instead will focus its resources on infectious disease vaccine programs along with cutting down expenses to conserve cash.

We note that Vical had cash and investments of approximately $66 million on Jun 30, 2013 which should roughly suffice operations through 2014 end.

Shares were down 57.26% on the trial failure news. The trial failure was disappointing as Allovectin was Vical's most advanced pipeline candidate.

With Allovectin being terminated, focus will now shift to ASP0113, a therapeutic vaccine candidate currently in a multinational phase III registration study for controlling cytomegalovirus (CMV) in hematopoietic cell transplant (HCT) recipients.

We remind investors that ASP0113 is being developed in collaboration with Astellas Pharma ( ALPMY ).

Meanwhile, Vical is also planning to begin a phase I/II clinical trial on Vaxfectin, a therapeutic vaccine against herpes simplex virus type 2 (HSV-2) before the end of 2013.

Vical currently carries a Zacks Rank #4 (Sell). Right now, Gilead Sciences ( GILD ) and Biogen Idec Inc. ( BIIB ) look attractive with a Zacks Rank #1 (Buy).


BIOGEN IDEC INC (BIIB): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

VICAL INC (VICL): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Business , Stocks
More Headlines for: ALPMY , BIIB , GILD , VICL

More from


Equity Research
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by